שווי כולל של החברה: Intellia Corp (NTLA)

The price history of Intellia Therapeutics (NTLA) on the GURU.Markets platform shows an Enterprise Value of 1502.14. Intellia Therapeutics is implementing CRISPR technologies, planning to establish premium pricing for its unique treatments in the future. However, geopolitical tensions are complicating equipment logistics and patent protection. High R&D costs and the probability of delayed complications create risks that are partially offset by the support of major industrial partners.

Intellia Therapeutics (NTLA) is scaling its CRISPR platform, advancing therapeutic candidates into late-stage trials. Enterprise Value, which aggregates market capitalization and debt minus cash, is used to value such a business. The current total valuation of the company stands at 1502.14. This calculation reflects the actual buyout price of the asset, accounting for liquidity. The trend of this metric allows investors to objectively compare the company's value against its commercialization potential.